1. Home
  2. CUE vs IPHA Comparison

CUE vs IPHA Comparison

Compare CUE & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cue Biopharma Inc.

CUE

Cue Biopharma Inc.

N/A

Current Price

$4.59

Market Cap

177.0M

Sector

Health Care

ML Signal

N/A

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$0.94

Market Cap

167.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CUE
IPHA
Founded
2014
1999
Country
United States
France
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
177.0M
167.6M
IPO Year
2017
2014

Fundamental Metrics

Financial Performance
Metric
CUE
IPHA
Price
$4.59
$0.94
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
★ $68.67
$7.00
AVG Volume (30 Days)
★ 552.6K
25.1K
Earning Date
11-16-2026
09-17-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 61.11
N/A
EPS
N/A
★ N/A
Revenue
★ $27,466,000.00
N/A
Revenue This Year
N/A
$427.26
Revenue Next Year
N/A
$88.11
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 195.75
N/A
52 Week Low
$0.17
$1.06
52 Week High
$45.50
$2.71

Technical Indicators

Market Signals
Indicator
CUE
IPHA
Relative Strength Index (RSI) 24.71 23.73
Support Level $0.22 N/A
Resistance Level $33.95 $1.59
Average True Range (ATR) 2.75 0.08
MACD -1.47 -0.04
Stochastic Oscillator 8.18 1.86

Price Performance

Historical Comparison
CUE
IPHA

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: